NT-proBNP and the Clinical Laboratory

Learn how a novel heart failure treatment impacts biomarker selection

Nov 6, 2019

P.A.C.E. CE contact hours: .5 hours

Duration: 29 minutes

Heart failure is a leading cause of death and disability in the United States. ENTRESTO®, a novel heart failure treatment, has been shown to increase life expectancy and reduce hospitalizations. As more patients are prescribed this medication, it is important to understand the potential implication in the clinical laboratory.


Dr. Jaeger reviews published data showing how levels of the biomarker BNP are affected in patients taking ENTRESTO and discusses the potential impact on risk assessment and clinical decision-making. Hear how you can lead change in your lab to support the use of this guideline-recommended medication that is helping patients with heart failure live longer.

ENTRESTO is a registered trademarks of Novartis AG.

References: Am Health Drug Benefits. 2015 Sep; 8(6): 330–334. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636283/ Accessed July 1, 2019.

This promotional educational activity is brought to you by Ortho Clinical Diagnostics and is not certified for Continuing Medical Education (CME). The speaker is presenting on behalf of Ortho Clinical Diagnostics and must present information in accordance with applicable and/or local regulatory country requirements.

About Our Speaker:
About Our Speaker:

Jared Jaeger, Ph.D.

Clinical Science Liaison, Ortho Clinical Diagnostics